The Christian-Albrechts-Universität zu Kiel (CAU)
The Christian-Albrechts-Universität zu Kiel (CAU)
uitklapper, klik om te openen
Partner Information uitklapper, klik om te openen
The Christian-Albrechts-Universität zu Kiel (Kiel University, CAU), founded 1665, uses research, teaching and the transfer of science to address the great challenges of our time in health, environmental and cultural change, nutrition and energy. The Faculty of Medicine is committed to medical and dental research and education. It particularly focuses on digital medicine and handling medical datasets. The pre-clinical and clinical-theoretical institutes are located on the CAU campuses, whereas the clinical departments can be found at the University Medical Center Schleswig-Holstein (UKSH) on its main campus in Kiel. The UKSH also consists a second major university hospital which is associated with the University of Lübeck. Both university hospitals are run as one entity making the UKSH one of the largest university medical centres in Europe with over 13.500 employees.
Departments involved with the STOPSTORM consortium are the departments of Radiation Oncology, of Internal Medicine III (cardiology) and of Radiology and Nuclear Medicine on the UKSH campus in Kiel. The Department of Radiation Oncology in Kiel employs experienced radiation oncologists and is equipped with the latest state-of-the-art radiation therapy systems for conventional radiotherapy, brachy-therapy and stereotactic radiotherapy. It also harbours an inpatient unit for combined radiation-oncologic treatments. The Department of Internal Medicine III (cardiology, angiology and intensive care) in Kiel has a dedicated electrophysiology unit equipped with the latest state-of-the-art catheter laboratory with high resolution epi- and endocardial mapping and ablation systems. The department has a cardiology intensity care unit fully equipped to handle patients with VT.
Personnel uitklapper, klik om te openen
Dr. Oliver Blanck
Dr. rer. hum. biol. Oliver Blanck is the research coordinator for stereotactic radiotherapy at the Department of Radiation Oncology (Kiel) and the head of operations, medical physics, and R&D at the Saphir Radiosurgery centres in Frankfurt and Kiel. He has 14 years of pioneering experience in STAR and will be responsible for coordinating all the partner activities within STOPSTORM. Dr. Blanck serves on the credentialing and audit committee of STOPSTOPM and as national coordinator will file all needed regulatory work for STOPSTORM for Germany. Dr. Blanck also oversees all activities in the work package quality assessment and assurance (WP4) and is responsible for all deliverables in WP4 for the STOPSTORM project.
In January 2024, Dr. Blanck became coordinator of the STOPSTORM consortium. His responsibilities include the day-to-day management of the STOPSTORM consortium together with the Management Board and Consortium Council.
Publications uitklapper, klik om te openen
- Krug D, Blanck O, Andratschke N, et al. Recommendations regarding cardiac stereotactic body radiotherapy for treatment refractory ventricular tachycardia: A Delphi Consensus statement. Heart Rhythm 2021; ISSN 1547-5271.
- Boda-Heggemann J, Blanck O, Mehrhof F, et al. Interdisciplinary clinical target volume generation for cardiac radioablation: Multi-center benchmarking for the RAdiosurgery for VENtricular TAchycardia (RAVENTA) trial. Int J Radiat Oncol Biol Phys 2021;S0360-3016(21)00088-2.
- Lydiard S, Blanck O, Hugo G, et al. A review of cardiac radioablation (CR) for arrhythmias: procedures, technology and future opportunities. Int J Radiat Oncol Biol Phys 2021;109(3):783-800.
- van der Ree MH, Blanck O, Limpens J, et al. Cardiac Radioablation – a Systematic Review. Heart Rhythm 2020;17(8):1381-1392.
- Blanck O, Buergy D, Vens M, et al. RAdiosurgery for VENtricular TAchycardia: Preclinical and clinical evidence and study design for a German multi-center multi-platform feasibility trial (RAVENTA). Clin Res Cardiol 2020;109(11):1319-1332.
- Krug D, Blanck O, Demming T, et al. Stereotactic body radiotherapy for ventricular tachycardia (cardiac radiosurgery): first-in-patient treatment in Germany. Strahlenther Onkol Strahlenther Onkol 2020; 196: 23-30.
- Schmitt D, Blanck O, Gauer T, et al. Technological quality requirements for stereotactic radiotherapy. Strahlenther Onkol 2020;196(5):421-443.
- Bode F, Blanck O, Gebhard M, et al. Pulmonary Vein Isolation by Radiosurgery: Implications for Non-invasive Treatment of Atrial Fibrillation. Europace 2015;17(12):1868-74.
- Blanck O, Bode F, Gebhard M, et al. Dose escalation study for cardiac radiosurgery in a porcine model. Int J Radiat Oncol Biol Phys 2014; 89: 590-8.
